Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
82.47%
-
Total 13F principal
-
$208,899,973
-
Principal change
-
-$13,829,027
-
Total reported market value
-
$173,045,653
-
Number of holders
-
34
-
Value change
-
-$9,513,086
-
Number of buys
-
9
-
Number of sells
-
15
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q2 2020
As of 30 Jun 2020,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
34 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$208,899,973
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, DeepCurrents Investment Group LLC, CITADEL ADVISORS LLC, OAKTREE CAPITAL MANAGEMENT LP, ADVENT CAPITAL MANAGEMENT /DE/, GOLDMAN SACHS GROUP INC, CNH PARTNERS LLC, CAMDEN ASSET MANAGEMENT L P /CA, Verition Fund Management LLC, and CAPSTONE INVESTMENT ADVISORS, LLC.
This page lists
34
institutional bondholders reporting positions
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.